Lantheus Holdings, Inc. (NASDAQ:LNTH) Holdings Decreased by MinichMacGregor Wealth Management LLC

MinichMacGregor Wealth Management LLC cut its position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 16.8% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 79,400 shares of the medical equipment provider’s stock after selling 15,978 shares during the quarter. Lantheus accounts for about 1.9% of MinichMacGregor Wealth Management LLC’s investment portfolio, making the stock its 20th largest holding. MinichMacGregor Wealth Management LLC owned about 0.11% of Lantheus worth $8,714,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of the business. GAMMA Investing LLC boosted its position in shares of Lantheus by 184.1% during the second quarter. GAMMA Investing LLC now owns 321 shares of the medical equipment provider’s stock worth $26,000 after buying an additional 208 shares during the period. Fidelis Capital Partners LLC bought a new position in shares of Lantheus in the first quarter worth $34,000. Signaturefd LLC increased its holdings in shares of Lantheus by 40.5% during the third quarter. Signaturefd LLC now owns 319 shares of the medical equipment provider’s stock valued at $35,000 after purchasing an additional 92 shares during the period. Nkcfo LLC bought a new stake in shares of Lantheus during the second quarter valued at about $47,000. Finally, UMB Bank n.a. lifted its holdings in Lantheus by 42.1% in the third quarter. UMB Bank n.a. now owns 425 shares of the medical equipment provider’s stock worth $47,000 after purchasing an additional 126 shares during the period. 99.06% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, President Paul Blanchfield sold 2,000 shares of the stock in a transaction on Thursday, August 8th. The stock was sold at an average price of $96.39, for a total value of $192,780.00. Following the completion of the sale, the president now owns 98,980 shares in the company, valued at $9,540,682.20. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other Lantheus news, Director Gerard Ber sold 15,500 shares of the company’s stock in a transaction that occurred on Monday, August 12th. The shares were sold at an average price of $96.48, for a total value of $1,495,440.00. Following the transaction, the director now owns 21,221 shares in the company, valued at approximately $2,047,402.08. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, President Paul Blanchfield sold 2,000 shares of the stock in a transaction that occurred on Thursday, August 8th. The stock was sold at an average price of $96.39, for a total transaction of $192,780.00. Following the completion of the sale, the president now owns 98,980 shares of the company’s stock, valued at approximately $9,540,682.20. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 1.50% of the company’s stock.

Lantheus Trading Down 4.3 %

Shares of Lantheus stock traded down $4.91 during trading on Tuesday, hitting $110.54. The stock had a trading volume of 296,201 shares, compared to its average volume of 953,683. The company has a quick ratio of 4.41, a current ratio of 4.68 and a debt-to-equity ratio of 0.55. The company has a market capitalization of $7.67 billion, a PE ratio of 18.93 and a beta of 0.51. Lantheus Holdings, Inc. has a 1 year low of $50.20 and a 1 year high of $126.89. The stock has a 50 day simple moving average of $108.30 and a 200 day simple moving average of $95.24.

Analyst Ratings Changes

A number of analysts have recently weighed in on LNTH shares. JMP Securities reduced their price target on shares of Lantheus from $130.00 to $125.00 and set a “market outperform” rating for the company in a research note on Thursday, August 1st. Truist Financial decreased their price target on Lantheus from $141.00 to $135.00 and set a “buy” rating for the company in a research note on Thursday, August 1st. Leerink Partners boosted their price objective on Lantheus from $106.00 to $127.00 and gave the stock an “outperform” rating in a research note on Thursday, July 11th. B. Riley raised their target price on Lantheus from $105.00 to $146.00 and gave the company a “buy” rating in a research note on Thursday, July 25th. Finally, Redburn Atlantic initiated coverage on shares of Lantheus in a research report on Tuesday, September 3rd. They issued a “buy” rating and a $175.00 price target on the stock. Two equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $126.00.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.